uniQure (QURE) announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy for the treatment of Fabry disease. Additionally, the Independent Data Monitoring Committee, IDMC, reviewed safety data from the initial two patients enrolled in the first cohort. The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial
- uniQure price target raised to $70 from $25 at H.C. Wainwright
- uniQure call volume above normal and directionally bullish
- uniQure prices 4.4M shares at $17.00 in public offering
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue